Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i
Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis
✍ Scribed by Manickam Venkatraman; Ruby John Anto; Asha Nair; Merina Varghese; Devarajan Karunagaran
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 325 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20116
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Cisplatin, a chemotherapeutic agent, is known to induce apoptosis of cancer cells. We examined the role of NF‐κB during cisplatin‐induced apoptosis in two human cervical cancer cell lines, HeLa and SiHa, known to differ in their response to cisplatin treatment. We found that SiHa cells were relatively more resistant than HeLa cells to the cytotoxic effects induced by cisplatin as measured by MTT assays. HeLa cells were more sensitive to the apoptotic effects induced by cisplatin as shown by increases in annexin staining, DNA fragmentation, and loss of mitochondrial membrane potential. Similarly the activities of caspases 3, 8, and 9 and cleavage of PARP induced by cisplatin were more in HeLa than SiHa cells. Cisplatin induced NF‐κB DNA binding activity in HeLa and SiHa cells but not in primary cervical cells and the active DNA binding complex in SiHa cells consists of p50 and RelA heterodimers. However, when NF‐κB DNA binding activity was blocked by chemical (curcumin, PDTC, or salicylic acid) or biological inhibitors (NIK‐KM or IKK‐β DN), the cell viability was less in SiHa cells with cisplatin treatment, but these effects were not observed in HeLa cells. Similarly upon treatment with cisplatin SiHa cells had more activation of caspases compared to that seen in HeLa cells under conditions of NF‐κB inhibition by biological or chemical inhibitors. These results suggest that NF‐κB may contribute to the resistance of human cervical cancer cells to cisplatin and highlight the potential use of combination therapy involving cisplatin and NF‐κB inhibitors. © 2005 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Among thyroid carcinomas, highly aggressive undifferentiated or anaplastic carcinomas still await effective therapeutic strategies. __R__‐roscovitine is a novel cyclin‐dependent kinase inhibitor in clinical trials as anti‐cancer agent. We have investigated the effects of __R__‐roscoviti
## Abstract The prostate‐apoptosis‐response‐gene‐4 (Par‐4) is up‐regulated in prostate cells undergoing programmed cell death. Furthermore, Par‐4 protein has been shown to function as an effector of cell death in response to various apoptotic stimuli that trigger mitochondria and membrane receptor‐
## Abstract Resistance to tumor necrosis factor (TNFα)‐induced apoptosis in various cancer cells has been attributed to the activation of the transcription factor NF‐κB. Ebselen (2‐phenyl‐1,2‐benzisoselenazol‐3[2H]one)—a selenoorganic compound is known to prevent TNFα‐mediated NF‐κB activity. As gl
In response to a diverse array of signals, IkappaBalpha is targeted for phosphorylation-dependent degradation by the proteasome, thereby activating NF-kappaB. Here we demonstrate a role of the cleavage product of IkappaBalpha in various death signals. During apoptosis of NIH3T3, Jurkat, Rat-1, and L